Jane Street’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $87.8M | Sell |
113,700
-21,800
| -16% | -$16.7M | 0.01% | 708 |
|
|
2025
Q4 | $105M | Sell |
135,500
-78,300
| -37% | -$53.2M | 0.02% | 566 |
|
|
2025
Q3 | $120M | Buy |
213,800
+170,900
| +398% | +$96.6M | 0.02% | 509 |
|
|
2025
Q2 | $22.5M | Buy |
42,900
+2,100
| +5% | +$1.17M | ﹤0.01% | 1340 |
|
|
2025
Q1 | $25.9M | Buy |
40,800
+16,400
| +67% | +$11.3M | 0.01% | 1095 |
|
|
2024
Q4 | $17.4M | Sell |
24,400
-4,100
| -14% | -$3.44M | ﹤0.01% | 1370 |
|
|
2024
Q3 | $30M | Buy |
28,500
+13,600
| +91% | +$15.1M | 0.01% | 980 |
|
|
2024
Q2 | $15.7M | Sell |
14,900
-8,900
| -37% | -$8.63M | ﹤0.01% | 1534 |
|
|
2024
Q1 | $22.9M | Sell |
23,800
-58,000
| -71% | -$55.2M | ﹤0.01% | 1091 |
|
|
2023
Q4 | $71.8M | Buy |
81,800
+33,900
| +71% | +$27.9M | 0.02% | 524 |
|
|
2023
Q3 | $39.4M | Sell |
47,900
-37,400
| -44% | -$29.4M | 0.01% | 669 |
|
|
2023
Q2 | $61.3M | Buy |
85,300
+22,600
| +36% | +$17.4M | 0.02% | 515 |
|
|
2023
Q1 | $51.5M | Sell |
62,700
-12,100
| -16% | -$9.13M | 0.02% | 511 |
|
|
2022
Q4 | $54M | Buy |
74,800
+10,600
| +17% | +$7.82M | 0.03% | 493 |
|
|
2022
Q3 | $44.2M | Sell |
64,200
-10,400
| -14% | -$6.55M | 0.02% | 570 |
|
|
2022
Q2 | $44.1M | Buy |
74,600
+5,300
| +8% | +$3.45M | 0.02% | 610 |
|
|
2022
Q1 | $48.4M | Sell |
69,300
-14,700
| -18% | -$9.3M | 0.02% | 697 |
|
|
2021
Q4 | $53M | Sell |
84,000
-11,900
| -12% | -$7.32M | 0.02% | 626 |
|
|
2021
Q3 | $58M | Buy |
95,900
+11,400
| +13% | +$7.08M | 0.02% | 543 |
|
|
2021
Q2 | $47.2M | Sell |
84,500
-21,500
| -20% | -$10.9M | 0.02% | 579 |
|
|
2021
Q1 | $50.2M | Sell |
106,000
-22,400
| -17% | -$10.9M | 0.02% | 484 |
|
|
2020
Q4 | $62M | Buy |
128,400
+57,700
| +82% | +$31.1M | 0.03% | 384 |
|
|
2020
Q3 | $39.6M | Buy |
70,700
+17,200
| +32% | +$10.4M | 0.02% | 472 |
|
|
2020
Q2 | $33.4M | Sell |
53,500
-900
| -2% | -$511K | 0.03% | 507 |
|
|
2020
Q1 | $26.6M | Sell |
54,400
-1,500
| -3% | -$619K | 0.03% | 370 |
|
|
2019
Q4 | $21M | Buy |
55,900
+25,400
| +83% | +$8.55M | 0.03% | 369 |
|
|
2019
Q3 | $8.46M | Sell |
30,500
-4,100
| -12% | -$1.21M | 0.01% | 681 |
|
|
2019
Q2 | $10.8M | Sell |
34,600
-3,000
| -8% | -$999K | 0.02% | 592 |
|
|
2019
Q1 | $15.4M | Buy |
37,600
+5,500
| +17% | +$2.26M | 0.03% | 504 |
|
|
2018
Q4 | $12M | Buy |
32,100
+2,700
| +9% | +$988K | 0.03% | 485 |
|
|
2018
Q3 | $11.9M | Buy |
29,400
+6,500
| +28% | +$2.47M | 0.02% | 514 |
|
|
2018
Q2 | $7.9M | Sell |
22,900
-52,600
| -70% | -$16.5M | 0.02% | 742 |
|
|
2018
Q1 | $26M | Buy |
75,500
+7,200
| +11% | +$2.5M | 0.07% | 226 |
|
|
2017
Q4 | $25.7M | Buy |
68,300
+27,100
| +66% | +$11M | 0.07% | 234 |
|
|
2017
Q3 | $18.4M | Buy |
41,200
+1,500
| +4% | +$714K | 0.06% | 291 |
|
|
2017
Q2 | $19.5M | Buy |
39,700
+1,600
| +4% | +$700K | 0.07% | 251 |
|
|
2017
Q1 | $14.8M | Sell |
38,100
-92,600
| -71% | -$34.3M | 0.07% | 260 |
|
|
2016
Q4 | $48M | Buy |
130,700
+106,500
| +440% | +$40.5M | 0.21% | 82 |
|
|
2016
Q3 | $9.73M | Sell |
24,200
-11,200
| -32% | -$4.49M | 0.05% | 320 |
|
|
2016
Q2 | $12.4M | Buy |
+35,400
| New | +$13.6M | 0.06% | 278 |
|
|
2016
Q1 | – | Sell |
-22,600
| Closed | -$12.3M | – | 4555 |
|
|
2015
Q4 | $12.3M | Buy |
22,600
+21,600
| +2,160% | +$11.7M | 0.08% | 225 |
|
|
2015
Q3 | $465K | Buy |
1,000
+100
| +11% | +$53.7K | ﹤0.01% | 2373 |
|
|
2015
Q2 | $459K | Hold |
900
| – | – | ﹤0.01% | 2373 |
|
|
2015
Q1 | $406K | Buy |
+900
| New | +$381K | ﹤0.01% | 2246 |
|
Other funds holding REGN
VCM
N
Jane Street's REGN Position: Q1 2026 in Review
Jane Street reduced its Regeneron Pharmaceuticals (REGN) stake by 57% in Q1 2026, selling an estimated $5.55M and leaving 5,374 shares worth $4.15M. The position accounts for ﹤0.01% of the portfolio, ranked #3783.
Jane Street first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $150M in Q2 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Jane Street held 5,374 shares of Regeneron Pharmaceuticals worth $4.15M as of Q1 2026.
- Jane Street sold 7,247 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $5.55M.
- Regeneron Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #3783 holding.
- Jane Street first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Jane Street's Regeneron Pharmaceuticals position peaked at $150M in Q2 2024.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.